Abstract
Oral anticoagulant therapy in patients with atrial fibrillation and concomitant malignancy is a serious clinical challenge. We present a case of a patient with prostate cancer treated with rivaroxaban due to a permanent atrial fibrillation. During a three-month follow-up period we did not observe any treatment-related adverse events.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
